NPPB and hydrops fetalis: The most recently published multicenter GUIDE-HF prospective, randomized clinical trial expanded enrollment to those with NYHA Class IIsymptoms who required medical attention within the previous year for worsening HFsymptoms or had elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP)levels despite maximally tolerated GDMT [17].